LT3337801T - (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido gamybos būdas ir (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido išskyrimas elektrocheminiais būdais - Google Patents

(4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido gamybos būdas ir (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido išskyrimas elektrocheminiais būdais

Info

Publication number
LT3337801T
LT3337801T LTEP16753390.0T LT16753390T LT3337801T LT 3337801 T LT3337801 T LT 3337801T LT 16753390 T LT16753390 T LT 16753390T LT 3337801 T LT3337801 T LT 3337801T
Authority
LT
Lithuania
Prior art keywords
naphthyridine
carboxamide
methoxyphenyl
dihydro
ethoxy
Prior art date
Application number
LTEP16753390.0T
Other languages
English (en)
Inventor
Johannes Platzek
Kathrin Gottfried
Jens Assmann
Giulio Lolli
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of LT3337801T publication Critical patent/LT3337801T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B15/00—Operating or servicing cells
    • C25B15/08—Supplying or removing reactants or electrolytes; Regeneration of electrolytes
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B15/00—Operating or servicing cells
    • C25B15/08—Supplying or removing reactants or electrolytes; Regeneration of electrolytes
    • C25B15/083—Separating products
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/01—Products
    • C25B3/05—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/01—Products
    • C25B3/07—Oxygen containing compounds
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/01—Products
    • C25B3/09—Nitrogen containing compounds
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/23—Oxidation
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/25—Reduction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEP16753390.0T 2015-08-21 2016-08-18 (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido gamybos būdas ir (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido išskyrimas elektrocheminiais būdais LT3337801T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15182040 2015-08-21
EP15182042 2015-08-21
PCT/EP2016/069567 WO2017032678A1 (de) 2015-08-21 2016-08-18 Verfahren zur herstellung von (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und wiedergewinnung von (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid mittels elektrochemischer methoden

Publications (1)

Publication Number Publication Date
LT3337801T true LT3337801T (lt) 2019-08-12

Family

ID=56694167

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16753390.0T LT3337801T (lt) 2015-08-21 2016-08-18 (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido gamybos būdas ir (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido išskyrimas elektrocheminiais būdais

Country Status (30)

Country Link
US (1) US10392384B2 (lt)
EP (1) EP3337801B1 (lt)
JP (1) JP6843120B2 (lt)
KR (1) KR102677034B1 (lt)
CN (1) CN108137587B (lt)
AU (1) AU2016311135C1 (lt)
CA (1) CA2995949A1 (lt)
CL (1) CL2018000426A1 (lt)
CO (1) CO2018001759A2 (lt)
DK (1) DK3337801T3 (lt)
ES (1) ES2739907T3 (lt)
HR (1) HRP20191476T1 (lt)
HU (1) HUE044678T2 (lt)
IL (1) IL257522B (lt)
JO (1) JOP20160185B1 (lt)
LT (1) LT3337801T (lt)
MX (1) MX367959B (lt)
NZ (1) NZ739993A (lt)
PE (1) PE20180555A1 (lt)
PL (1) PL3337801T3 (lt)
PT (1) PT3337801T (lt)
RS (1) RS59086B1 (lt)
RU (1) RU2715226C2 (lt)
SG (1) SG11201801378VA (lt)
SI (1) SI3337801T1 (lt)
TW (1) TWI725044B (lt)
UA (1) UA124418C2 (lt)
UY (1) UY36863A (lt)
WO (1) WO2017032678A1 (lt)
ZA (1) ZA201801867B (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3560922A1 (de) * 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
AU2019414285B2 (en) * 2018-12-24 2024-11-14 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Chemical compound manufacture, new salt form, and therapeutic uses thereof
CN110195238B (zh) * 2019-04-15 2020-08-14 浙江工业大学 一种三氯甲基吡啶衍生物电化学脱氯制备酰胺的方法
CN110195239B (zh) * 2019-04-15 2020-08-14 浙江工业大学 一种多氯甲基吡啶衍生物电化学脱氯制备醛、酸的方法
CN111910206B (zh) * 2019-05-07 2023-03-10 中国科学技术大学 一种合成3-氰基取代的咪唑并[1,5-a]喹啉类化合物的方法
MX2021015987A (es) * 2019-06-21 2022-04-06 Xerion Advanced Battery Corp Metodos para extraer litio de espodumeno.
PE20221415A1 (es) * 2019-10-17 2022-09-20 Bayer Ag Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxi-fenil)-5-hidroxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxilato de 2-cianoetilo por separacion de racematos por medio de ester de acido tartarico diastereoisomero
AU2020365314B2 (en) * 2019-10-17 2026-05-14 Bayer Aktiengesellschaft Process for producing acyloxymethyl esters of (4S)-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylic acid
CR20220157A (es) * 2019-10-17 2022-06-02 Bayer Ag Procedimiento para preparar (4s)–4–(4–ciano–2–metoxi–fenil)–5–etoxi–2,8–dimetil–1,4–dihidro–1,6–naftiridin–3–carboxilato de 2–cianoetilo mediante separación de racematos utilizando ésteres diastereoméricos de ácido tartárico
EP4045502A1 (de) 2019-10-17 2022-08-24 Bayer Aktiengesellschaft Photochemisches verfahren zur herstellung von (4r, 4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid
TW202214624A (zh) 2020-06-16 2022-04-16 德商拜耳廠股份有限公司 藉由催化不對稱漢斯（ｈａｎｔｚｓｃｈ）酯還原法進行之製備（４ｓ）－４－（４－氰基－２－甲氧基苯基）－５－乙氧基－２，８－二甲基－１，４－二氫－１，６－㖠啶－３－羧醯胺的方法
CN113214248B (zh) * 2021-04-13 2022-04-26 湖南南新制药股份有限公司 一种1,4-二氢-1,6-萘啶衍生物、药物组合物及其用途
CN113897631B (zh) * 2021-10-24 2023-05-09 昆明学院 电化学合成吡啶-2-酮衍生物的方法
CN114149427A (zh) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 非奈利酮及其中间体的合成方法
CN115340539B (zh) 2022-01-19 2024-02-27 奥锐特药业股份有限公司 制备非奈利酮及其中间体的方法
CN114605410B (zh) * 2022-04-06 2023-12-29 浙江科聚生物医药有限公司 一种非奈利酮原料药的制备方法
EP4511365A1 (en) 2022-04-18 2025-02-26 Teva Pharmaceuticals International GmbH Processes for the preparation of finerenone
CN117304067A (zh) * 2022-06-21 2023-12-29 南京工业大学 一种非奈利酮中间体4-氰基-2-甲氧基苯甲醛的合成方法
CN115583866A (zh) * 2022-08-30 2023-01-10 上海厚博生物科技有限公司 一种用非奈利酮对映体制备非奈利酮的方法
CR20250241A (es) * 2022-12-16 2025-08-08 Bayer Ag Síntesis secuencial en un solo recipiente para la preparación de 4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida
CN117946102A (zh) * 2024-01-08 2024-04-30 江苏德源药业股份有限公司 一种非奈利酮非对映体盐及其制备非奈利酮的方法
CN117903131A (zh) * 2024-01-10 2024-04-19 浙江车头制药股份有限公司 一种非奈利酮的改进合成方法
CN117945947A (zh) * 2024-01-26 2024-04-30 江西凯信生物医药有限公司 一种2-甲氧基-4-氰基苯甲醛的合成方法
CN119684288B (zh) * 2024-12-18 2026-04-17 中山百盛生物技术有限公司 非奈利酮的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
DE3431303A1 (de) * 1984-08-25 1986-02-27 Goedecke Ag 1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung
WO2007007018A1 (en) 2005-07-12 2007-01-18 Glaxo Group Limited Piperazine heteroaryl derivates as gpr38 agonists
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102007009494A1 (de) * 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung

Also Published As

Publication number Publication date
RS59086B1 (sr) 2019-09-30
JOP20160185B1 (ar) 2021-08-17
MX2018002236A (es) 2018-03-23
CN108137587B (zh) 2020-10-23
JP2018523697A (ja) 2018-08-23
IL257522A (en) 2018-04-30
AU2016311135C1 (en) 2022-10-13
PT3337801T (pt) 2019-08-05
RU2715226C2 (ru) 2020-02-26
BR112018003334A2 (pt) 2018-09-18
IL257522B (en) 2020-04-30
TW201722943A (zh) 2017-07-01
UY36863A (es) 2017-03-31
RU2018109762A (ru) 2019-09-23
HRP20191476T1 (hr) 2019-11-15
UA124418C2 (uk) 2021-09-15
EP3337801A1 (de) 2018-06-27
US10392384B2 (en) 2019-08-27
AU2016311135A1 (en) 2018-03-15
HUE044678T2 (hu) 2019-11-28
CL2018000426A1 (es) 2018-07-20
PE20180555A1 (es) 2018-04-02
KR102677034B1 (ko) 2024-06-24
PL3337801T3 (pl) 2019-10-31
CA2995949A1 (en) 2017-03-02
EP3337801B1 (de) 2019-06-12
MX367959B (es) 2019-09-12
US20180244668A1 (en) 2018-08-30
WO2017032678A1 (de) 2017-03-02
DK3337801T3 (da) 2019-08-19
SG11201801378VA (en) 2018-03-28
HK1252212A1 (zh) 2019-05-24
ZA201801867B (en) 2019-10-30
CO2018001759A2 (es) 2018-02-28
TWI725044B (zh) 2021-04-21
NZ739993A (en) 2022-05-27
AU2016311135B2 (en) 2020-09-10
JP6843120B2 (ja) 2021-03-17
KR20180043305A (ko) 2018-04-27
ES2739907T3 (es) 2020-02-04
SI3337801T1 (sl) 2019-08-30
CN108137587A (zh) 2018-06-08
RU2018109762A3 (lt) 2019-12-18

Similar Documents

Publication Publication Date Title
HUE044678T2 (hu) Eljárás (4S)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboxamid elõállítására és (4S)-4-(4-ciano-2-metoxifenil)-5-etoxi- 2,8-dimetil-1,4-dihidro-1-6-naftiridin-3-karboxamid visszanyerésére elektrokémiai módszerekkel
UY40247A (es) Procedimiento para la preparación de (4S)- 4-(4-Ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihid
IL282156A (en) Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
IL259931A (en) Neoantigen identification, manufacture, and use
DK3134553T3 (da) Kolorimetrisk detektering af nukleinsyreamplifikation
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
LT3337800T (lt) (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido, skirto naudoti kaip veikliojo farmacinio ingrediento, gamybos būdas ir gryninimas
BR112017025542A2 (pt) compostos de naftiridina como inibidores de quinase jak
DK3253267T3 (da) Blender med aftagelig spindel og overvåget reservoir
CL2016002461A1 (es) Derivados macrocíclicos de pirimidina
DK3310340T3 (da) Formulering med høj koncentration
BR112016020889A2 (pt) variantes de hppd e métodos de uso
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3021545T3 (da) Høreapparat med en autentificeringsprotokol
DK3166612T3 (da) Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxy-picolinsyre
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
DK3362453T3 (da) Cykliske etherderivater af pyrazolo[1,5-a]pyrimidin-3-carboxyamid
DK3173071T3 (da) Formularing af maropitant
PL3417294T3 (pl) Sposoby obejmujące stałe, przerywane dawkowanie cedyranibu
IL248578A0 (en) Quinzoline derivatives, pharmaceutical compounds containing them and their uses
EP3287522A4 (en) DETECTION OF FGFR2
BR112017012240A2 (pt) métodos de preparação de composições contendo alcaloides e suas utilizações
ZA201801865B (en) Method for the preparation of the metabolites of (4s)- and (4r)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and the use thereof
FR3041605B1 (fr) Coupole de rotor, rotor et giravion
EP3204774A4 (en) Methods for simultaneous determination of serological profile and estimation of duration post hiv infection